Authors: P. Bavor; M. Kučerová; A. Mušálková; A. Stolz Authors‘ workplace: Chirurgická klinika 2. LF UK a FN Motol a Homolka, Praha Published in: Rozhl. Chir., 2026, roč. 105, č. 4, s. 169-173. Category: Review doi: https://doi.org/10.48095/ccrvch2026169
Thyroid carcinomas are rare among other human malignancies. Their incidence shows an increasing trend with the growing availability and accuracy of diagnostic options. Examination of a patient with thyroid disease relies on medical history, clinical examination, laboratory findings, and imaging studies, among which ultrasonography has been the method of choice for several decades. The range of genetic methods in clinical practice is continually expanding. The principles of treatment for differentiated carcinoma have been established for many decades. Current attention is focused on genetic testing and expanding the possibilities of biological treatment. Surgical treatment of thyroid diseases had very poor outcomes for nearly 1,000 years, with high mortality and morbidity. The refinement of surgical techniques, technological progress, and a number of medical discoveries made safe and radical thyroid surgery possible. From the era of extensive surgeries in the second half of the 20th century, there has been a gradual de-escalation of surgical procedures. National and international organization guidelines serve to provide a unified approach to patients at different stages of differentiated thyroid carcinoma, and are updated and refined hand in hand with the development of diagnostic and therapeutic options. Guidelines from professional societies for the treatment of differentiated thyroid carcinomas are dynamically evolving, not entirely uniform, and are meant to serve as recommendations that allow the surgeon to optimize treatment while considering the individual patient, with a tendency toward de-escalation of surgical procedures.
Key words
guidelines – differentiated thyroid carcinoma – de-escalation of treatment
1. Astl J. Chirurgická léčba nemocí štítné žlázy. Praha: Jesenius Maxdorf 2014.
2. Kopečková K. Nádory štítné žlázy. Praha: Mladá fronta 2019.
3. Vlček P. Karcinom štítné žlázy – pooperační sledování nemocných. Praha: Maxdorf 2022.
4. Pekova B, Dvorakova S, Sykorova V et al. Somatic genetic alterations in a large cohort of pediatric thyroid nodules. Endocr Connect 2019; 8 (6): 796–805. doi: 10.1530/EC-19-0069.
5. Astl J, Chovanec M, Lukeš P et al. Thyroid carcinoma surgery in children and adolescents – 15 years experience surgery of pediatric thyroid carcinoma. Int J Pediatr Otorhinolaryngol 2014; 78 (7): 990–994. doi: 10.1016/j.ijporl.2014.03.005.
6. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102 (9): 605–613. doi: 10.1093/jnci/djq099.
7. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 1985; 56 (3): 531–538. doi: 10.1002/1097-0142 (1985 0801) 56 : 3<531:: aid-cncr2820560321>3.0.co; 2-3.
8. Xing M. Genetic-guided risk assessment and management of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48 (1): 109–124. doi: 10.1016/j.ecl.2018.11.007.
9. Roy M, Chen H, Sippel R. Current understanding and management of medullary thyroid cancer. Oncologist 2016; 18 (10): 1093–1100. doi: 10.1634/theoncologist.2013-0053.
10. Tan SY, Shigaki D. Emil Theodor Kocher (1841–1917): thyroid surgeon and Nobel laureate. Singapore Med J 2008; 49 (9): 662–663.
11. Kendall EC, Osterberg AE. The chemical identification of thyroxin. J Biol Chem 1919; 40 (2): 265–334. doi: 10.1016/s0021-9258 (18) 87246-5.
12. Carter P. The life and legacy of William T. Bovie. Am J Surg 2013; 205 (5): 488–491. doi: 10.1016/j.amjsurg.2012.12.005.
13. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33 (6): 920–980. doi: 10.1210/er.2012-1030.
14. Lundgren CI, Zedenius J, Skoog L. Fine--needle aspiration biopsy of benign thyroid nodules: an evidence-based review. World J Surg 2008; 32 (7): 1247–1252. doi: 10.1007/s00268-008-9578-9.
15. Hoang JK, Nguyen XV, Davies L. Overdiagnosis of thyroid cancer: answers to five key questions. Acad Radiol 2015; 22 (8): 1024–1029. doi: 10.1016/j.acra.2015.01.019.
16. Hamous J, Dvořák J, Bušovský I et al.Hashimotos thyroiditis. Rozhl Chir 2021; 100 (3): 110–112. doi: 10.33699/PIS.2021.100.3.110-112.
17. Kovatch KJ, Hoban CW, Shuman AG. Thyroid cancer surgery guidelines in an era of de-escalation. Eur J Surg Oncol 2017; 44 (3): 297–306. doi: 10.1016/j.ejso.2017.03.005.
18. Vaccarella S, Franceschi S, Bray F. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016; 375 (7): 614–617. doi: 10.1056/NEJMp1604412.
19. Haugen BR, Alexander EK, Bible KC. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (1): 1–133. doi: 10.1089/thy.2015.0020.
20. Nikiforov YE, Seethala RR, Tallini G. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2 (8): 1023–1029. doi: 10.1001/jamaoncol.2016.0386.
21. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol 2018; 44 (3): 307–315. doi: 10.1016/j.ejso.2017.03.004.
22. Šafránek J, Třeška V, Skalický T et al.Differentiated thyroid microcarcinoma current perspective. Rozhl Chir 2020; 99 (11): 497–501. doi: 10.33699/PIS. 2020.99.11.497–501.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
